Hwa An Announces IND Submission to FDA for Phase II Clinical Trial of Parkinson's Oral Drug ENERGI-F705PD
Hwa An has announced the submission of an Investigational New Drug (IND) application to the U.S. FDA… · 2026-06-26
Hwa An has announced the submission of an Investigational New Drug (IND) application to the U.S. FDA… · 2026-06-26
Hua An Company has been invited to participate in an investor conference hosted by Grand Cathay Secu… · 2026-06-11
Huaan held its Annual General Meeting on May 22, approving the 114th fiscal year financial statement… · 2026-05-22
Formosa Biomedical Technology Corp. (華安) announced that its Board of Directors approved the Q1 2026 … · 2026-05-08
Formosa Biomedical Technology Corp. (華安) announced that its Board of Directors approved the Q1 2026 … · 2026-05-08
Hwa An (stock code: 6657), a biotechnology and healthcare company, announced its revenue for May 202… · 2026-05-01
Hua An announced that its board of directors meeting to review the Q1 2026 financial report will be … · 2026-04-30
Hua An announced that its board of directors meeting to review the Q1 2026 financial report will be … · 2026-04-30
HUA AN announced April 2026 revenue of 0.01 billion TWD, a significant 89.9% increase year-over-year… · 2026-04-01
HUA AN announced April 2026 revenue of 0.01 billion TWD, a significant 89.9% increase year-over-year… · 2026-04-01
Huaan reported March 2026 revenue of 0.01 billion yuan, a significant 50.2% increase year-on-year. T… · 2026-03-01
Huaan reported March 2026 revenue of 0.01 billion yuan, a significant 50.2% increase year-on-year. T… · 2026-03-01
Waan Medical announced its financial data for February 2026, with a monthly revenue of NT$270,000 (a… · 2026-02-01
Waan Medical announced its financial data for February 2026, with a monthly revenue of NT$270,000 (a… · 2026-02-01